Related Experiment Video
Updated: Mar 23, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Prevention of hepatitis B virus-associated liver diseases by antiviral therapy
Akinobu Tawada1,2, Tatsuo Kanda3, Fumio Imazeki2
1Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Insights
Hepatitis B virus (HBV) infection can lead to severe liver disease. Current treatments include nucleos(t)ide analogues (NUCs) and peginterferon, with vaccination preventing new infections.
Area of Science:
- Hepatology
- Virology
- Public Health
Background:
- Hepatitis B virus (HBV) is a significant cause of liver disease globally, especially in Asia-Pacific regions.
- HBV infection can lead to chronic hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma (HCC).
- Some individuals develop HCC even without cirrhosis.
Purpose of the Study:
- To review currently available treatments for Hepatitis B virus infection.
- To discuss the management of HBV-related complications like HCC and liver failure.
- To highlight the role of vaccination in preventing HBV transmission.
Main Methods:
- Literature review of existing HBV treatments.
- Analysis of treatment efficacy for preventing fibrosis and complications.
- Discussion of challenges in managing HBV infection and its sequelae.
Main Results:
- Nucleos(t)ide analogues (NUCs) can prevent liver fibrosis and complications but require long-term administration.
- Peginterferon may lead to HBV surface antigen loss.
- NUCs are effective for acute liver failure and acute exacerbations of chronic hepatitis B.
Conclusions:
- Continuous treatment with NUCs is necessary for managing HBV infection.
- Peginterferon use is limited in patients with decompensated cirrhosis.
- Universal HBV vaccination is crucial for global prevention of new infections.
Abstract:
Hepatitis B virus (HBV) is a major cause of acute and chronic hepatitis, cirrhosis and hepatocellular carcinoma, particularly in Asia-Pacific countries. The major complications in HBV carriers are hepatocellular carcinoma (HCC), liver failure and esophageal varices following the progression to cirrhosis, while some develop HCC without cirrhosis. The progression to liver fibrosis and these other complications could be prevented by treatment with nucleos(t)ide analogues (NUCs); however, NUCs must be continuously administered for a long time. Peginterferon could lead to HBV surface antigen loss. It is difficult to use peginterferon in HBV-infected patients with decompensated cirrhosis. Acute liver failure due to HBV infection and acute exacerbation of chronic hepatitis B could be treated by NUCs. Universal vaccination programs against HBV could prevent new HBV infections globally. Here, we review the currently available treatments for HBV infection.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Viruses with RNA Genomes
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...